Abstract
According to the Japanese Ministry of Health, Labour and Welfare (MHLW), pneumonia is the fourth leading cause of death in Japan. Respiratory tract infection such as pneumonia is important for the elderly patients. Thus, the development of DDS with the aim of reducing the frequency of dosing and improving compliance is also suggestive of a new trend for DDS in the field of treating Respiratory tract infection.
Azithromycin-SR will be released as the choice for community-acquired pneumonia in near future. Liposomal amphotericin B for empirical therapy in patients with deep seated mycosis is useful for clinicians. Inhaled amikacin and the new pulmonary drug delivery system have been expected as the new treatment for the patients infected with resistant bacteria.
